Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib

Abstract

Hui Qu,1,2 ZhaoHui Xu,1,2 YanYing Ren,1 ZeZhong Gong,1,2 Ri Hyok Ju,1,2 Fan Zhang,1 HaoNan Kang,1,2 Yang Xu,1,2 Xin Chen1 1Department of Hernia and Colorectal Surgery, The Second Hospital of Dalian Medical University, Dalian, 116023, People’s Republic of China; 2Dalian Medical University, Dalian, People’s Republic of ChinaCorrespondence: Xin Chen, Tel [phone], Email [email protected]: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of the gastrointestinal tract, with an annual incidence of 10– 15 cases per million. However, rectal GIST has a low incidence, accounting for approximately 0.1% of all rectal tumors. The treatment of rectal GISTs is still controversial and the relative unified guidelines and consensus opinions are inadequate. Treatment is based primarily on the clinical experience of the physician. The widespread application of neoadjuvant imatinib therapy allows diversification of treatment, especially in the choice of surgical methods. Herein, we reviewed the most recent literature and summarized the new progress in rectal tumor treatment, with the aim of providing patients with more systematic and individualized therapeutic strategies.Keywords: gastrointestinal stromal tumors, GIST, rectum, laparoscopy, surgery, neoadjuvant imatinib

Keywords

• gastrointestinal stromal tumors (gist)
• rectum
• laparoscopy
• surgery
• neoadjuvant imatinib